32771-73-6

Upstream product

• 118-48-9 isatoic anhydride 
• 3182-93-2 ethyl 2-amino-3-phenylpropanoate hydrochloride 
• 1795-96-6 phenylalanine ethyl ester 

Downstream Products

• 620167-33-1 2(R,S)-{2-[(1H-indole-5-carbonyl)-amino]-benzoylamino}-3-phenyl-propionic aicd ethyl ester 
• 620167-32-0 2(R,S)-{2-[(1H-indole-2-carbonyl)-amino]-benzoylamino}-3-phenyl-propionic acid ethyl ester 
• 620167-34-2 2(R,S)-{2-[(1H-indole-3-carbonyl)-amino]-benzoylamino}-3-phenyl-propionic acid ethyl ester 
• 620167-36-4 2-[2-(3-1H-indol-3-yl-propionylamino)-benzoylamino]-3-phenyl-propionic acid ethyl ester 
• 620167-45-5 2(R,S)-[2-(2-adamantan-1-yl-acetylamino)-benzoylamino]-3-phenyl-propionic acid ethyl ester 
• 620167-38-6 2(R,S)-[2-(naphthalene-1-sulfonylammino)-benzoylamino]-3-phenyl-propionic acid ethyl ester 
• 620167-42-2 2(R,S)-[2-(2,2-dimethyl-propionylamino)-benzoylamino]-3-phenyl-propionic acid ethyl ester 
• 620167-44-4 2(R,S)-{2-[(adamantane-1-carbonyl)-amino]-benzoylamino}-3-phenyl-propionic acid ethyl ester 
• 620167-41-1 3-phenyl-2(R,S)-[2-(3-phenyl-propionylamino)-benzoylamino]-propionic acid ethyl ester 
• 620167-37-5 2(R,S)-{2-[(naphthalene-1-carbonyl)-amino]-benzoylamino}-3-phenyl-propionic acid ethyl ester 
• 685141-95-1 3-phenyl-2(RS)-{2-[(pyridine-4-carbonyl)-amino]-benzoylamino}-propionic acid ethyl ester 

Relevant academic research and scientific papers

Synthesis of N-terminal substituted anthranilic acid dimer derivatives for evaluation on CCK receptors

A series of new N-substituted anthranilic acid dimer derivatives having a C-terminal Phe residue was synthesized and evaluated for their affinity for CCK receptors. These compounds resulted from a blended approach based firstly on the use of an alternative substructure embedded within asperlicin and secondly on the derivatization of this template with substituents chosen considering the C-terminal primary structure of the endogenous ligand. Although these compounds exhibited a regnylogical-type organization similar to that of CCK-4, they are characterized by about 1000-fold greater affinity for CCK-A receptor than the C-terminal tetrapeptide.

Anthranilic acid based CCK1 antagonists: The 2-indole moiety may represent a "needle" according to the recent homonymous concept

Recently we described an innovative class of non-peptide CCK1 antagonists keeping appropriate pharmacophoric groups on the anthranilic acid employed as a molecular scaffold. The lead compound obtained, VL-0395, characterized by the presence of Phe and the 2-indole moiety at the C- and N-termini of anthranilic acid, respectively, is endowed with submicromolar affinity towards CCK1 receptors. Thus, we have prepared and tested on CCK receptors a library of VL-0395 analogues in order to investigate the precise topological and essential key interactions of the 2-indole group of the lead with the CCK1 receptor. The obtained results confirm that this group establishes very specific interactions with this receptor sub-site and may be viewed as a "needle" group.

ANTHRANYL DERIVATIVES HAVING AN ANTICHOLECYSTOKININ ACTIVITY (ANTI-CCK-1), A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL USE THEREOF

Anthranylic compounds having anti-CCK activity of general formula (I) in which, n is a whole number lying between 0 and 7; R1 is chosen independently from the groups (II), in which X1 is chosen independently from, S, O, NR2/sub

Anthranilic acid derivatives: A new class of non-peptide CCK1 receptor antagonists

Having successfully obtained new CCK1 ligands holding appropriate groups on the anthranilic acid dimer used as molecular scaffold we were interested in increasing their micromolar affinity for the CCK1 receptors by modifying the spatial relationship of the main pharmacophoric groups. Since, we have proposed simplified analogues reducing the anthranilic acid dimer to a monomer. In this stage of our research program we have prepared and tested on CCK receptors a series of N-substituted anthranilic acid derivatives keeping a Phe residue at the C-terminal site. The indole-2-carbonyl group imparts the best CCK1 receptor binding affinity (compound 1: IC50=197.5 nM) while a sharp decrease in binding affinity is observed for the other indole containing derivatives. Moreover, in order to support the different binding behaviour observed for the synthesized compounds, a conformational investigation was carried out. Finally, on the basis of the main pharmacophoric groups of the obtained new lead compound (1) (coded VL-0395) a receptor binding hypothesis has been provided.

C-terminal anthranoyl-anthranilic acid derivatives and their evaluation on CCK receptors

A series of C-terminal anthranoyl-anthranilic acid derivatives arising from a strict bond disconnection approach of asperlicin were synthesized and examined for their CCK receptor affinities. These compounds represent the second step of our investigation